Navigation Links
Pharmasset Reports Fiscal Year End 2008 Financial Results
Date:12/11/2008

PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported financial results for the fiscal year ended September 30, 2008. At September 30, 2008, Pharmasset held $63.6 million in cash and cash equivalents and short term investments.

Pipeline Update and 2008 Highlights

Clevudine

During 2008, new data from multiple investigator sponsored studies supported the potential of clevudine to treat hepatitis B (HBV), including its use in lamivudine resistant patients. Data from one study suggested that clevudine is as effective as entecavir (Baraclude(R)) and that it can be effectively used in combination with adefovir (Hepsera(R)). Management believes the unique attributes of clevudine will help to differentiate it in the marketplace, including its potential to achieve a sustained virological response (SVR) in patients after a defined treatment period.

In July of 2008, the French National Agency for Research on AIDS and Viral Hepatitis initiated a study to compare treatment with clevudine or tenofovir with a combination of the two. In this study patients will be treated for two years, followed by a determination of the SVR rates.

Pharmasset is currently enrolling two registration trials worldwide (studies 305 and 306) and as a result of unforeseen regulatory delays that impacted the start up in certain countries, the company expects to complete enrollment at the end of the first calendar quarter of 2009.

R7128

During 2008, Pharmasset made significant progress with our hepatitis C virus (HCV) programs. R7128, our lead HCV nucleoside inhibitor, completed 28 day clinical studies in both treatment n
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
3. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
4. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
5. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
6. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
7. Pharmasset Receives Notice of Allowance
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 Today, iHealth Lab Inc. announced ... Ventures, Ltd. for its first institutional round of funding. ... iHealth,s global reach, accelerate growth and innovation, and invest ... the investment, Xiaomi Ventures will join iHealth,s board of ... infrastructure and ecommerce. "We are very pleased ...
(Date:9/19/2014)... , September 19, 2014 ... ) has announced the addition of the ... report to their offering.      ... have been broadly classified into wide categories ... used for the treatment of different gynecological ...
(Date:9/19/2014)... , Sept. 19, 2014  The board of ... declared a quarterly cash dividend of $0.42 per share.  ... 17, 2014 to stockholders of record at the close ... AbbVie AbbVie is a global, research-based biopharmaceutical company formed ... is to use its expertise, dedicated people and unique ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
... Calif., April 14 Researchers at,the Barbara ... been studying,racial disparities related to cancer patients. ... (AACR) Annual Meeting, Karmanos researchers,Vitaly Balan, Ph.D., ... their abstract, Galectin-3 nsSNP rs4644 Foretells Human ...
... 14 Perrigo Company,(Nasdaq: PRGO ; ... final approval,from the U.S. Food and Drug ... Cetirizine Hydrochloride Oral Solution,(Allergy) and Children,s Cetirizine ... will be marketed under store brand labels ...
Cached Medicine Technology:Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women 2Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women 3Perrigo Announces Approval for Over-the-Counter Children's Cetirizine Oral Solution 2
(Date:9/19/2014)... leading Dartmouth researcher, working with The Melanoma Genetics Consortium, ... today in the Journal of the National Cancer ... of melanoma. , "For the first time, we have ... telomeres play a part in the risk of developing ... PhD, School of Medicine at the University of Leeds ...
(Date:9/19/2014)... News) -- U.S. military troops deployed to sunny climates ... to a new study. Many returning troops ... some cases, military personnel developed blisters on their skin ... size of their moles since being deployed overseas. ... skin cancer, the study authors noted. "The past ...
(Date:9/19/2014)... The U.S. Food and Drug Administration approved a new type ... a class of once-a-week injectable drugs that help manage blood ... "Trulicity is a new treatment option, which can be used ... sugar levels in the overall management of type 2 diabetes," ... Drug Evaluation II, said in an agency news release. ...
(Date:9/19/2014)... 2014 MetroMD, a leading anti-ageing clinic has ... of human health. This therapy has grown tremendously across USA ... more effective, safe and dependable. It has far reaching benefits ... to live a very healthy and active lifestyle even beyond ... therapy, a senior therapist at MetroMD said, “HGH or Human ...
(Date:9/19/2014)... - New research published today in the online journal ... reach 6,800 in West Africa by the end of ... , Arizona State University and Harvard University researchers ... rise in cases significantly increased in August in Liberia ... was put in place, indicating that the mass quarantine ...
Breaking Medicine News(10 mins):Health News:Melanoma risk found to have genetic determinant 2Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:Research predicts possible 6,800 new Ebola cases this month 2
... April 2010 - Elsevier, the world-leading publisher of ... proudly announces the release of a brand-new single ... mitral valve disease by the internationally renowned cardiac ... will launch at the 90th Annual Meeting of ...
... ... and printing products, today announced it is ready for immediate shipping of thousands of ... through customer service or instantly online from the company’s award winning web site My1Stop.com. ... Ft. Scott, ...
... ... money with FatWallet’s expert selection of deals for Mother’s Day. Experienced experts research the ... and seasonal categories such as laptops, HDTVs, Father’s Day and graduation. , ... (PRWEB) April 26, 2010 -- ...
... ... Documentation by Integrating Electronic Medical Forms Generated During the Pre-operative Process into Core ... ... important new level of clinical integration designed to provide immediate access to patient ...
... ... area residents safe and effective cosmetic and aesthetic treatments. Advanced Aesthetics utilizes top ... ... The art of aesthetics is continually changing. As technology progresses, innovative treatments replace ...
... that factors known to increase the risk of breast cancer ... Published early online in Cancer , a peer-reviewed journal ... is needed to evaluate how breast cancer risk factors differ ... frequently in certain ethnic and racial groups, but the reasons ...
Cached Medicine News:Health News:Elsevier launches Carpentier's reconstructive valve surgery book 2Health News:My1Stop.com New Packaging Supplies Offering for Distribution Centers and Small Business Shipping 2Health News:Expert Approved: FatWallet Guides Mother's Day Shoppers to the Best Deals Online 2Health News:SourceMedical Provides Ambulatory Surgery Centers with New Levels of Document Integration for Easy Access to Patient Data 2Health News:SourceMedical Provides Ambulatory Surgery Centers with New Levels of Document Integration for Easy Access to Patient Data 3Health News:In Coeur d'Alene Idaho, Top Of The Line Aesthetic Treatments And Non-Invasive Laser Technology Can Be Found Only At Advanced Aesthetics 2Health News:In Coeur d'Alene Idaho, Top Of The Line Aesthetic Treatments And Non-Invasive Laser Technology Can Be Found Only At Advanced Aesthetics 3Health News:Breast cancer risk factors differ among races 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... provide a broad selection of ... a wide variety of ophthalmic ... is packaged sterile, complete with ... switch in the "off " ...
... provide a broad selection of ... a wide variety of ophthalmic ... is packaged sterile, complete with ... switch in the "off " ...
Medicine Products: